<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Seasonal influenza in nonpregnant adults: Treatment
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Seasonal influenza in nonpregnant adults: Treatment
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Seasonal influenza in nonpregnant adults: Treatment
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kimon C Zachary, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Martin S Hirsch, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elinor L Baron, MD, DTMH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 22, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Seasonal influenza is an acute respiratory illness caused by influenza A or B viruses [
         <a href="#rid1">
          1-3
         </a>
         ]. Influenza occurs in outbreaks and epidemics worldwide, mainly during the winter season in temperate climates. Influenza is usually a self-limited infection; however, it is associated with increased morbidity and mortality in certain high-risk patient groups.
        </p>
        <p>
         The United States Centers for Disease Control and Prevention (CDC) has issued recommendations for the use of antivirals for influenza [
         <a href="#rid1">
          1
         </a>
         ]. The Infectious Diseases Society of America (IDSA) published updated influenza guidelines in 2018 [
         <a href="#rid2">
          2
         </a>
         ]. Our recommendations are generally in keeping with those of the CDC and IDSA.
        </p>
        <p>
         Issues related to treatment of seasonal influenza will be reviewed here. Issues related to use of antiviral agents for prevention of seasonal influenza are discussed separately, as are the pharmacologic characteristics of the antiviral drugs and issues related to antiviral drug resistance. (See
         <a class="medical medical_review" href="/z/d/html/7017.html" rel="external">
          "Seasonal influenza in adults: Role of antiviral prophylaxis for prevention"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7008.html" rel="external">
          "Antiviral drugs for influenza: Pharmacology and resistance"
         </a>
         .)
        </p>
        <p>
         Management of pregnant patients with seasonal influenza is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/15870.html" rel="external">
          "Seasonal influenza and pregnancy", section on 'Management'
         </a>
         .)
        </p>
        <p>
         Issues related to avian influenza are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7002.html" rel="external">
          "Avian influenza: Epidemiology and transmission"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7001.html" rel="external">
          "Avian influenza: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/138869.html" rel="external">
          "Avian influenza: Treatment and prevention"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3404854138">
         <span class="h1">
          GENERAL PRINCIPLES
         </span>
        </p>
        <p class="headingAnchor" id="H509567413">
         <span class="h2">
          Site of care
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hospitalization is warranted for patients with significant dehydration and for severely ill patients, especially those with respiratory distress, hypoxemia, impaired cardiopulmonary function, or altered mental status. In the absence of these findings, admission for observation may be warranted for patients with increased risk for complications  (
         <a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">
          table 1
         </a>
         ) and uncertain clinical trajectory.
        </p>
        <p class="headingAnchor" id="H1032389810">
         <span class="h2">
          Symptom management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hydration should be maintained.
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          Acetaminophen
         </a>
         or nonsteroidal anti-inflammatory drugs may be used for management of fever, headache, and myalgia.
        </p>
        <p class="headingAnchor" id="H689731049">
         <span class="h1">
          HOSPITALIZED PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Criteria for hospitalization are discussed above. (See
         <a class="local">
          'Site of care'
         </a>
         above.)
        </p>
        <p>
         The clinical approach for management of hospitalized patients includes antiviral treatment as well as evaluation and treatment for concomitant infection.
        </p>
        <p class="headingAnchor" id="H1523580588">
         <span class="h2">
          Antiviral therapy
         </span>
        </p>
        <p class="headingAnchor" id="H73095794">
         <span class="h3">
          Timing of treatment
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical approach
         </strong>
         − For patients hospitalized with known or suspected influenza, we administer antiviral treatment promptly, regardless of symptom duration.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Initiation of antiviral treatment should not be delayed while awaiting the results of diagnostic testing [
         <a href="#rid1">
          1
         </a>
         ]. In addition, treatment should not be withheld from patients with high clinical suspicion for influenza but negative rapid antigen test results, given inadequate diagnostic sensitivity. For hospitalized patients with negative molecular diagnostic testing and persistent clinical suspicion for influenza, empiric antiviral treatment should be continued while additional diagnostic specimens are obtained. (See
         <a class="medical medical_review" href="/z/d/html/7004.html" rel="external">
          "Seasonal influenza in adults: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supporting evidence
         </strong>
         − Some observational data suggest decreased mortality risk associated with antiviral treatment [
         <a href="#rid4">
          4-6
         </a>
         ]. There are no available assessments of mortality from randomized trials because such trials have been conducted among healthy individuals (with low influenza mortality rate).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In one meta-analysis including 78 observational studies and 29,234 hospitalized patients with influenza during the 2009-2010 influenza A H1N1 pandemic, treatment with a neuraminidase inhibitor treatment (irrespective of timing) was associated with a reduction in mortality risk (adjusted odds ratio 0.81, 95% CI 0.70-0.93). In addition, treatment within two days of symptom onset was associated with a reduction in mortality risk (adjusted OR 0.48, 95% CI 0.41-0.56) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a cohort study including 1330 patients with influenza requiring intensive care, early treatment with
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         (within 48 hours of symptoms) was associated with lower mortality (relative risk 0.69, 95% CI 0.49 to 0.94) [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, early initiation of antiviral treatment among hospitalized patients has been associated with reduced length of stay [
         <a href="#rid7">
          7,8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1946354201">
         <span class="h3">
          Antiviral selection
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preferred regimen
         </strong>
         −
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          Oseltamivir
         </a>
         is the preferred antiviral agent for treatment of influenza; dosing is summarized in the table  (
         <a class="graphic graphic_table graphicRef50350" href="/z/d/graphic/50350.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There is no role for increasing the
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         dose, given lack of benefit [
         <a href="#rid9">
          9,10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Based on available data, there is no role for routine use of combination antiviral therapy for treatment of influenza [
         <a href="#rid2">
          2,11-13
         </a>
         ]. In one trial including more than 360 hospitalized patients with severe influenza treated with a neuraminidase inhibitor and randomly assigned to treatment with or without
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          baloxavir
         </a>
         , no difference in clinical outcomes (including time to clinical improvement) was observed [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alternative regimens
         </strong>
         − Alternative antiviral agents for treatment of severe influenza include
         <a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">
          peramivir
         </a>
         or
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         (both administered parenterally):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">
          Peramivir
         </a>
         may be used for patients who cannot tolerate oral therapy; while peramivir has been approved by the US Food and Drug Administration for treatment of uncomplicated influenza [
         <a href="#rid1">
          1,2
         </a>
         ], we think its use is reasonable for patients with severe influenza who cannot tolerate oral agents. In such cases we favor administration of 600 mg intravenously once daily for five days (rather than a single dose) [
         <a href="#rid14">
          14
         </a>
         ]. In some cases, an extended treatment course may be warranted; this is discussed further below.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In regions where parenteral
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         is available (eg, the United Kingdom and the European Union), this agent may be used if other antiviral agents cannot be used. The usual duration of treatment for parenteral zanamivir is 5 to 10 days [
         <a href="#rid15">
          15
         </a>
         ]. Inhaled zanamivir should not be used for treatment of severe influenza given limited data.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          Baloxavir
         </a>
         should not be used for treatment of severe influenza given limited efficacy data.
        </p>
        <p>
        </p>
        <p>
         Efficacy data and adverse effects of antiviral agents are discussed below. (See
         <a class="local">
          'Antiviral efficacy and adverse effects'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2586484241">
         <span class="h3">
          Antiviral duration
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, we administer antiviral treatment to hospitalized patients for five days.
        </p>
        <p>
         For patients with ongoing symptoms of severe lower respiratory tract disease (particularly in the setting of immunosuppression), an extended duration of antiviral treatment (up to 10 days) may be reasonable, particularly in those who continue to have detectable viral RNA from a respiratory specimen after 5 days of antiviral treatment [
         <a href="#rid2">
          2,16,17
         </a>
         ]. (See
         <a class="local">
          'Antiviral resistance'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H336971283">
         <span class="h2">
          Concomitant infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients who present with respiratory failure and/or hemodynamic instability warrant further diagnostic evaluation. (See
         <a class="medical medical_review" href="/z/d/html/7004.html" rel="external">
          "Seasonal influenza in adults: Clinical manifestations and diagnosis", section on 'Additional diagnostic evaluation'
         </a>
         .)
        </p>
        <p>
         Empiric treatment for concomitant bacterial infection is warranted for patients with influenza in the following circumstances [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients presenting with respiratory failure and/or hemodynamic instability
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who fail to improve or clinically deteriorate after three to five days of antiviral therapy and supportive care
        </p>
        <p>
        </p>
        <p>
         The diagnostic evaluation for concomitant infection is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7004.html" rel="external">
          "Seasonal influenza in adults: Clinical manifestations and diagnosis", section on 'Additional diagnostic evaluation'
         </a>
         .)
        </p>
        <p>
         For patients in the above circumstances, administration of empiric antibacterial treatment for pneumonia is reasonable (in addition to antiviral treatment for influenza) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         Antibiotic selection should be guided by Gram stain and culture of sputum, if available. If the etiology of the pneumonia is uncertain, empiric antibiotics effective against the organisms commonly implicated in secondary bacterial pneumonia among patients with influenza (
         <em>
          Streptococcus pneumoniae
         </em>
         ,
         <em>
          Streptococcus pyogenes,
         </em>
         and
         <em>
          Staphylococcus aureus
         </em>
         )
         <em>
         </em>
         should be used.
        </p>
        <p>
         Agents with activity against
         <em>
          S. pneumoniae
         </em>
         and
         <em>
          S. pyogenes
         </em>
         include a third-generation cephalosporin (such as
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         ) or a respiratory fluoroquinolone (eg,
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         or
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         ). Empiric treatment for methicillin-resistant
         <em>
          S. aureus
         </em>
         infection with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         or
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         should be initiated in patients with severe or necrotizing pneumonia [
         <a href="#rid2">
          2,18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7031.html" rel="external">
          "Treatment of community-acquired pneumonia in adults in the outpatient setting"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">
          "Treatment of community-acquired pneumonia in adults who require hospitalization"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4136117251">
         <span class="h2">
          Infection control
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infection control measures for prevention of seasonal influenza are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6999.html" rel="external">
          "Infection control measures for prevention of seasonal influenza"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H92905968">
         <span class="h1">
          OUTPATIENTS
         </span>
        </p>
        <p class="headingAnchor" id="H638004411">
         <span class="h2">
          Clinical approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to clinical decision-making regarding outpatient antiviral therapy is summarized in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef140873" href="/z/d/graphic/140873.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3887583400">
         <span class="h3">
          Patients at risk for complications or severe illness
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical approach
         </strong>
         – For the following outpatients with known or suspected influenza A or B (regardless of symptom duration), we suggest antiviral treatment [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients at increased risk for complications  (
         <a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">
          table 1
         </a>
         )
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with progressive illness who do not require hospitalization
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In such cases, antiviral treatment may reduce the duration of illness and reduce the risk of respiratory tract complications; it may or may not reduce the risk of hospitalization.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supporting evidence
         </strong>
         − For outpatients with increased risk for complications, the impact of antiviral treatment on the risk of hospitalization is uncertain:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a 2024 systematic review and meta-analysis including 15 randomized trials and 6166 adult outpatients with influenza infection (median age 45 years; 54 percent treated with
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         ), oseltamivir was not associated with reduced risk of hospitalization (relative risk 0.79; 95% confidence interval [CI] 0.48-1.29; risk difference -0.17 percent; 95% CI -0.23 to 0.48 percent) [
         <a href="#rid19">
          19
         </a>
         ]. Oseltamivir was also not associated with reduced hospitalization among patients age ≥65 years (relative risk 1.01; 95% CI 0.21-4.90)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In contrast to the above findings, in a 2015 meta-analysis including 4328 adult outpatients (of whom approximately 70 percent were older patients with comorbidities) in 9 randomized trials comparing
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         treatment (within 36 hours) with placebo, those treated with oseltamivir had shorter median time to symptom resolution (97.5 versus 122.7 hours; difference -25.2, 95% CI -36.2 to -16.0), fewer lower respiratory tract complications requiring antibiotic treatment (4.9 versus 8.7 percent; risk ratio 0.56, 95% CI 0.42-0.75), and a modest difference in hospitalization rate (0.6 versus 1.7 percent; risk difference -1.1 percent, 95% CI -1.4 to 0.3) [
         <a href="#rid20">
          20
         </a>
         ]. Adverse effects included nausea and vomiting.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3956813782">
         <span class="h3">
          Patients who may transmit infection
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical approach
         </strong>
         − For outpatients with known or suspected influenza A or B (regardless of symptom duration) who have exposure to individuals at increased risk for influenza complications  (
         <a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">
          table 1
         </a>
         ), such as household contacts and health care workers, we suggest antiviral treatment [
         <a href="#rid1">
          1,2
         </a>
         ]. In such cases, antiviral treatment may reduce the likelihood of transmission to vulnerable individuals.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3573212164">
         <span class="h3">
          Patients who are not at high risk for complications or transmission
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical approach
         </strong>
         −
         <strong>
         </strong>
         For outpatients with uncomplicated illness who are not at increased risk for complications  (
         <a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">
          table 1
         </a>
         ), treatment should be guided by duration of symptoms:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Symptoms &lt;48 hours – For patients within 48 hours of symptom onset, whether to administer antiviral treatment should be guided by shared clinical decision-making; treatment may be associated with a modest reduction in duration of illness (by approximately 24 hours).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Symptoms ≥48 hours – For patients beyond 48 hours of symptom onset, we suggest not administering antiviral treatment, given lack of proven benefit.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Supporting evidence
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Symptoms &lt;48 hours: For outpatients with uncomplicated influenza, early antiviral treatment (within 48 hours of symptom onset) may be associated with a modest reduction in duration of illness (by approximately 24 hours) [
         <a href="#rid20">
          20-24
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Neuraminidase inhibitors – In a review including 20
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         trials and 46
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         trials among healthy individuals, oseltamivir reduced the time to first alleviation of symptoms among adults by 16.8 hours (95% CI 8.4-25.1 hours) and zanamivir reduced the time to first alleviation of symptoms among adults by 14.4 hours (0.60 days; 95% CI 0.39-0.81 days) [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          Baloxavir
         </a>
         – In a randomized trial including 2184 outpatients ≥12 years with uncomplicated influenza treated with baloxavir or placebo, baloxavir treatment was associated with a reduction in the median time to symptom improvement by 29 hours (95% CI 14.6-42.8) [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Symptoms ≥48 hours: In a randomized trial including 496 patients with influenza in Bangladesh enrolled ≥48 after illness onset (of whom 40 were ≥18 years of age), the median duration of symptoms was similar in both groups (
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         3 days [interquartile range 2 to 5], placebo 3 days [1 to 5]) [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1250225177">
         <span class="h2">
          Antiviral selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          Oseltamivir
         </a>
         is the preferred antiviral agent for treatment of influenza; it is the agent with the most established efficacy and safety. Dosing is summarized in the table  (
         <a class="graphic graphic_table graphicRef50350" href="/z/d/graphic/50350.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         Alternative antiviral agents for treatment of uncomplicated influenza include
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          baloxavir
         </a>
         (oral single dose),
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         (inhaled regimen twice daily for five days), or
         <a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">
          peramivir
         </a>
         (parenteral single dose)  (
         <a class="graphic graphic_table graphicRef50350" href="/z/d/graphic/50350.html" rel="external">
          table 2
         </a>
         ). Clinical considerations for selection among these agents include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          Baloxavir
         </a>
         should not be used for treatment of immunocompromised hosts; its use has been associated with emergence of resistance [
         <a href="#rid22">
          22,23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          Zanamivir
         </a>
         is contraindicated in patients with asthma or chronic obstructive pulmonary disease because of the risk of bronchospasm.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">
          Peramivir
         </a>
         should be reserved for patients who cannot tolerate oral or inhaled agents.
        </p>
        <p>
        </p>
        <p>
         Efficacy data and adverse effects of antiviral agents are discussed below. (See
         <a class="local">
          'Antiviral efficacy and adverse effects'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2030988536">
         <span class="h2">
          Antiviral duration
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with uncomplicated influenza, the treatment duration for
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         or
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         is five days; the treatment duration for
         <a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">
          peramivir
         </a>
         or
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          baloxavir
         </a>
         consists of a single dose  (
         <a class="graphic graphic_table graphicRef50350" href="/z/d/graphic/50350.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1437324254">
         <span class="h2">
          Infection control and returning to work/school
         </span>
         <span class="headingEndMark">
          —
         </span>
         Use of face masks and hand hygiene may reduce household transmission. Individuals with influenza should remain home from work, school, and other public places until at least 24 hours after resolution of fever (without use of antipyretics) and improvement in symptoms.
        </p>
        <p>
         Infection control measures for prevention of seasonal influenza are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/6999.html" rel="external">
          "Infection control measures for prevention of seasonal influenza"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H146025757">
         <span class="h1">
          PATIENTS WITH PERSISTENT SYMPTOMS
         </span>
        </p>
        <p class="headingAnchor" id="H2206825733">
         <span class="h2">
          Evaluation and treatment for bacterial infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to diagnostic evaluation for and empiric treatment of bacterial infection for patients with influenza is described above. (See
         <a class="local">
          'Concomitant infection'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3038381889">
         <span class="h2">
          Antiviral resistance
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         − Factors associated with the emergence of antiviral drug resistance include the administration of postexposure prophylaxis with a neuraminidase inhibitor (particularly if underdosed), immunosuppression, and prolonged antiviral treatment [
         <a href="#rid26">
          26,27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Clinicians should remain informed about current surveillance data on the frequency and geographic distribution of neuraminidase inhibitor-resistant influenza viruses during influenza season [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In general,
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         resistance (and
         <a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">
          peramivir
         </a>
         cross-resistance) is rare; since 2009, 99 percent of influenza virus isolates tested in the United States have been susceptible to neuraminidase inhibitors [
         <a href="#rid1">
          1,28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7008.html" rel="external">
          "Antiviral drugs for influenza: Pharmacology and resistance", section on 'Drug resistance'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          Baloxavir
         </a>
         resistance may occur more commonly than resistance to neuraminidase inhibitors; in one randomized trial including more than 1000 patients with influenza treated with baloxavir,
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         , or placebo, emergence of viral escape mutants with reduced drug susceptibility was observed in 10 percent of patients treated with baloxavir [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          When to suspect drug resistance
         </strong>
         − Evaluation for antiviral resistance should be pursued for patients in the following circumstances [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients who develop influenza infection while receiving or immediately following receipt of antiviral prophylaxis with a neuraminidase inhibitor.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Immunocompromised patients and patients with severe influenza who remain ill despite treatment with a neuraminidase inhibitor, with evidence of persistent influenza virus replication (demonstrated by persistently positive reverse-transcriptase polymerase chain reaction or viral culture results after 7 to 10 days of antiviral therapy).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with persistent symptoms of influenza who were treated with subtherapeutic dosing of a neuraminidase inhibitor or
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          baloxavir
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In such cases, a respiratory sample should be sent to the state laboratory for resistance testing, where phenotypic and/or genotypic assays are performed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – If
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         resistance is suspected, neither oseltamivir nor
         <a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">
          peramivir
         </a>
         should be used.
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          Zanamivir
         </a>
         is the preferred treatment, as such resistance usually does not extend to zanamivir [
         <a href="#rid2">
          2
         </a>
         ]. If inhaled zanamivir cannot be used, oral
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          baloxavir
         </a>
         is an option. Intravenous zanamivir is available in the European Union and the United Kingdom, but not in the United States. (See
         <a class="medical medical_review" href="/z/d/html/7008.html" rel="external">
          "Antiviral drugs for influenza: Pharmacology and resistance", section on 'Drug resistance'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In one study including 68 patients with resistant H1N1 virus infection during the 2008-2009 influenza season treated with oral
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         or inhaled
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         , the duration of fever after the first dose was longer among patients treated with oseltamivir (49 versus 28 hours), confirming correlation between in vitro susceptibility and clinical effectiveness [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Thus far,
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          baloxavir
         </a>
         has not been adequately studied for treatment of oseltamivir-resistant influenza. Emergence of resistance after a single dose of baloxavir raises concerns about the long-term utility of this drug as monotherapy [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2469472304">
         <span class="h1">
          ANTIVIRAL AGENTS
         </span>
        </p>
        <p class="headingAnchor" id="H341214517">
         <span class="h2">
          Antiviral drug classes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Classes of antiviral drugs for treatment of influenza include  (
         <a class="graphic graphic_table graphicRef50350" href="/z/d/graphic/50350.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid1">
          1-3
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neuraminidase inhibitors
         </strong>
         – Neuraminidase inhibitors include
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         ,
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         , and
         <a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">
          peramivir
         </a>
         (active against influenza A and B). Neuraminidase inhibitors interfere with release of progeny influenza virus from infected cells, thereby preventing new rounds of infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Endonuclease inhibitor
         </strong>
         −
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          Baloxavir
         </a>
         is a selective inhibitor of influenza cap-dependent endonuclease (active against influenza A and B).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adamantanes
         </strong>
         – Adamantanes include
         <a class="drug drug_general" data-topicid="8508" href="/z/d/drug information/8508.html" rel="external">
          amantadine
         </a>
         and
         <a class="drug drug_general" data-topicid="9866" href="/z/d/drug information/9866.html" rel="external">
          rimantadine
         </a>
         (active against influenza A). These drugs target the M2 protein of influenza A, which forms a proton channel in the viral membrane that is essential for viral replication.
        </p>
        <p>
        </p>
        <p>
         Due to emergence of high rates of adamantane resistance among influenza A viruses, the United States Centers for Disease Control and Prevention recommends that adamantanes
         <strong>
          not
         </strong>
         be used for the treatment of influenza in the United States [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3652309335">
         <span class="h2">
          Antiviral efficacy and adverse effects
         </span>
        </p>
        <p class="headingAnchor" id="H4108822739">
         <span class="h3">
          Oseltamivir
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         − Treatment with
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         may shorten the duration of influenza symptoms by approximately one day [
         <a href="#rid20">
          20,24,25,30,31
         </a>
         ] and reduce the duration of viral shedding [
         <a href="#rid25">
          25,32
         </a>
         ]. Some studies have also shown that oseltamivir reduces illness severity and complication rates [
         <a href="#rid20">
          20,33
         </a>
         ], hospital admission rates [
         <a href="#rid20">
          20,34
         </a>
         ], and length of hospital stay [
         <a href="#rid35">
          35,36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Most of the evidence supporting use of antiviral therapy for treatment of influenza is based on data from trials evaluating the efficacy of
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         . These data are summarized above. (See
         <a class="local">
          'Timing of treatment'
         </a>
         above and
         <a class="local">
          'Clinical approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some data suggest lower efficacy of
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         for reducing symptoms in the setting of infection due to influenza B. In a study in Japan including 1818 patients with influenza A and 1485 patients with influenza B treated with oseltamivir, the duration to resolution of fever was longer for patients with influenza B (mean duration 65 versus 48 hours) [
         <a href="#rid37">
          37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         −
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          Oseltamivir
         </a>
         can cause nausea and vomiting [
         <a href="#rid20">
          20
         </a>
         ], but these adverse effects do not generally result in drug discontinuation. There have been reports of delirium in patients (primarily children) receiving oseltamivir for treatment of influenza. Most of these reports came from Japan, where the drug is used more commonly than in the United States [
         <a href="#rid38">
          38
         </a>
         ]. However, subsequent studies have not demonstrated a causal association between oseltamivir and neuropsychiatric events [
         <a href="#rid39">
          39,40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5985.html" rel="external">
          "Seasonal influenza in children: Management", section on 'Efficacy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H457383631">
         <span class="h3">
          Zanamivir
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          Zanamivir
         </a>
         is administered by inhalation. An intravenous formulation is available in some regions (United Kingdom and the European Union) but is not available in the United States.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Treatment with
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         may shorten the duration of influenza symptoms. In a 2014 meta-analysis including 26 randomized trials of healthy adults and children with influenza (obtained from the manufacturer of zanamivir and the European Medicines Agency), treatment with zanamivir was associated with shortened median time to symptom resolution by 14.4 hours (95% CI 9.4-19.4 hours) [
         <a href="#rid41">
          41
         </a>
         ]. A reduction in the risk of pneumonia, hospital admission, or mortality was not observed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The efficacy of parenteral
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         appears comparable with that of oral
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         ; in a trial including 626 hospitalized patients randomly assigned to treatment with parenteral zanamivir or oral oseltamivir, the median time to clinical response was comparable between the groups [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         –
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          Zanamivir
         </a>
         (inhaled) can cause bronchospasm in patients with asthma and other chronic respiratory disorders; therefore, this agent is contraindicated in these patient groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          Zanamivir
         </a>
         inhalation powder is not recommended for use in nebulizers or mechanical ventilators since the carrier can clog ventilator tubing [
         <a href="#rid43">
          43,44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4062109406">
         <span class="h3">
          Peramivir
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">
          Peramivir
         </a>
         is administered parenterally; it is approved by the US Food and Drug Administration (FDA) for treatment of uncomplicated influenza infection in adults who have been ill for ≤2 days.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         − Among outpatients, the efficacy of
         <a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">
          peramivir
         </a>
         appears to be comparable with that of
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         . In a randomized trial including 1091 adults with uncomplicated influenza infection randomly assigned to receive peramivir (600 mg intravenous [IV] single dose) or oseltamivir, symptom duration was comparable between the groups [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Among hospitalized patients, the benefit of
         <a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">
          peramivir
         </a>
         remains uncertain due to limited data. In one randomized trial including 121 hospitalized patients treated with peramivir (600 mg IV once daily for five days) or placebo, a benefit of peramivir was not observed [
         <a href="#rid14">
          14
         </a>
         ]. In another randomized trial including 40 hospitalized patients treated with peramivir (300 IV once daily for 5 days) or
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         , symptom duration was comparable between the groups [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         − Diarrhea is a common adverse effect reported in patients receiving
         <a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">
          peramivir
         </a>
         . Rare but serious adverse effects associated with peramivir include skin or hypersensitivity reactions such as Stevens-Johnson syndrome and erythema multiforme. In addition, there have been postmarketing reports of neuropsychiatric events from Japan [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3612913262">
         <span class="h3">
          Baloxavir
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          Baloxavir
         </a>
         is administered orally; it is approved by the FDA for treatment of uncomplicated influenza in adults who have been ill for ≤2 days. Emergence of resistance after a single dose has raised concerns about the long-term utility of baloxavir monotherapy [
         <a href="#rid22">
          22,23
         </a>
         ]; issues related to antiviral resistance are discussed further separately. (See
         <a class="medical medical_review" href="/z/d/html/7008.html" rel="external">
          "Antiviral drugs for influenza: Pharmacology and resistance"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         − Treatment with
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          baloxavir
         </a>
         may shorten the duration of influenza symptoms by approximately one day [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a randomized trial (CAPSTONE-1) including more than 1000 otherwise healthy outpatients with uncomplicated influenza randomly assigned to treatment with
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          baloxavir
         </a>
         ,
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         , or placebo, the median time to resolution of symptoms was 53.7 hours with baloxavir versus 80.2 hours with placebo [
         <a href="#rid22">
          22
         </a>
         ]. The time to resolution of symptoms was similar with baloxavir and oseltamivir.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a subsequent trial (CAPSTONE-2) including more than 1000 outpatients at high risk of influenza complications  (
         <a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">
          table 1
         </a>
         ) randomly assigned to treatment with
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          baloxavir
         </a>
         ,
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         , or placebo, the efficacy of baloxavir and oseltamivir were similar (median time to resolution of symptoms was 73 hours and 81 hours, respectively) and superior to placebo (median time to resolution of symptoms was 102 hours), respectively [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         − Adverse effects include diarrhea (1.8 percent of
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          baloxavir
         </a>
         recipients compared with 1.3 percent of placebo recipients and 1.4 percent of
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         recipients) [
         <a href="#rid22">
          22
         </a>
         ]. Hypersensitivity reactions (eg, anaphylaxis, urticaria, angioedema, erythema multiforme) have been reported in postmarketing surveillance [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Investigational approaches
         </span>
         <span class="headingEndMark">
          —
         </span>
         Investigational approaches for treatment of influenza include parenteral and/or long-acting formulations of neuraminidase inhibitors [
         <a href="#rid49">
          49
         </a>
         ] and antiviral agents with novel mechanisms of action [
         <a href="#rid50">
          50,51
         </a>
         ]. Based on available data, there is no role for routine use of combination antiviral therapy for treatment of influenza; this is discussed above. (See
         <a class="local">
          'Antiviral selection'
         </a>
         above.)
        </p>
        <p>
         A number of adjunctive therapies have been proposed for the management of patients with influenza, thus far, none has sufficient evidence to support its use:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Statins – It has been hypothesized that the anti-inflammatory effects of statins could reduce the severity of illness associated with influenza infection; randomized trials are needed. (See
         <a class="medical medical_review" href="/z/d/html/4546.html" rel="external">
          "Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease", section on 'Reduced inflammation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Glucocorticoids – There has been interest in the potential for glucocorticoids to improve outcomes in patients with influenza infection by reducing inflammation. However, in a meta-analysis of observational studies, glucocorticoid use was associated with an increased mortality risk (odds ratio 3.90, 95% CI 2.31-6.60) [
         <a href="#rid52">
          52
         </a>
         ]. Given the possibility of harm, glucocorticoids should not be used as adjunctive therapy for treatment of patients with influenza in the absence of a separate indication for their use [
         <a href="#rid2">
          2,53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intravenous immunoglobulin, convalescent plasma, and hyperimmune globulin – There has been interest in use of these agents as adjunctive therapy for severe influenza infection [
         <a href="#rid54">
          54
         </a>
         ]; further study is needed [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H361334152">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111532.html" rel="external">
          "Society guideline links: Treatment and prevention of seasonal influenza with antivirals"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/15369.html" rel="external">
          "Patient education: Flu (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/4010.html" rel="external">
          "Patient education: Influenza symptoms and treatment (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H29">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General principles
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Site of care
         </strong>
         − Hospitalization is warranted for patients with significant dehydration and for severely ill patients, especially those with respiratory distress, hypoxemia, impaired cardiopulmonary function, or altered mental status. In the absence of these findings, admission for observation may be warranted for patients with increased risk for complications  (
         <a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">
          table 1
         </a>
         ) and uncertain clinical trajectory. (See
         <a class="local">
          'Site of care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Symptom management
         </strong>
         − Hydration should be maintained.
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          Acetaminophen
         </a>
         or nonsteroidal anti-inflammatory drugs may be used for management of fever, headache, and myalgia. (See
         <a class="local">
          'Symptom management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hospitalized patients
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antiviral treatment
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Timing
         </strong>
         − For hospitalized patients with known or suspected influenza presenting &lt;48 hours after symptom onset, we recommend antiviral treatment (
         <a class="grade" href="https:///uptodate/show/grade_3" rel="external">
          Grade 1C
         </a>
         ); for those presenting ≥48 hours after symptom onset, we suggest antiviral treatment (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Timing of treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Antiviral selection
         </strong>
         − We suggest treatment with
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Alternative agents include
         <a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">
          peramivir
         </a>
         or
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         (administered parenterally). Dosing is summarized in the table  (
         <a class="graphic graphic_table graphicRef50350" href="/z/d/graphic/50350.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Antiviral selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          Zanamivir
         </a>
         (inhaled) is contraindicated in patients with asthma or chronic obstructive pulmonary disease, and it should not be used for treatment of severe influenza (given limited data).
         <a class="drug drug_general" data-topicid="9527" href="/z/d/drug information/9527.html" rel="external">
          Peramivir
         </a>
         (parenteral) should be reserved for patients who cannot tolerate oral or inhaled agents.
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          Baloxavir
         </a>
         should not be used for treatment of severe influenza (given limited data) or immunocompromised hosts (given concern for emergence of resistance).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Concomitant infection
         </strong>
         − For patients in the following circumstances, we suggest administration of empiric antibacterial treatment for pneumonia (in addition to antiviral treatment for influenza) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ) (see
         <a class="local">
          'Concomitant infection'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Patients with respiratory failure and/or hemodynamic instability
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Patients who fail to improve after three to five days of antiviral therapy and supportive care
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Patients who develop fever after defervescence
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Patients should be treated with an agent active against
         <em>
          Streptococcus pneumoniae
         </em>
         and
         <em>
          Streptococcus pyogenes
         </em>
         (such as
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">
          levofloxacin
         </a>
         , or
         <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">
          moxifloxacin
         </a>
         ). In addition, for patients with severe or necrotizing pneumonia, empiric treatment for methicillin-resistant
         <em>
          Staphylococcus aureus
         </em>
         infection (with
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         or
         <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">
          linezolid
         </a>
         ) should be administered.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outpatients
         </strong>
         – The approach to decision-making regarding outpatient antiviral therapy is summarized in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef140873" href="/z/d/graphic/140873.html" rel="external">
          algorithm 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Outpatients at risk for complications or severe illness
         </strong>
         – For the following outpatients with known or suspected influenza A or B (regardless of symptom duration), we suggest antiviral treatment  (
         <a class="graphic graphic_algorithm graphicRef140873" href="/z/d/graphic/140873.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Patients at increased risk for complications  (
         <a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">
          table 1
         </a>
         )
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Patients with progressive illness who do not require hospitalization
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In such cases, antiviral treatment may reduce the duration of illness and reduce the risk of respiratory tract complications and hospitalization. (See
         <a class="local">
          'Patients at risk for complications or severe illness'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Outpatients who may transmit infection to high-risk contacts
         </strong>
         − For outpatients with known or suspected influenza A or B (regardless of symptom duration) who have exposure to individuals at increased risk for influenza complications  (
         <a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">
          table 1
         </a>
         ), such as household contacts and health care workers, we suggest antiviral treatment  (
         <a class="graphic graphic_algorithm graphicRef140873" href="/z/d/graphic/140873.html" rel="external">
          algorithm 1
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In such cases, antiviral treatment may reduce the likelihood of transmission to vulnerable individuals. (See
         <a class="local">
          'Patients who may transmit infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Outpatients who are not at high risk for complications or transmission
         </strong>
         − For outpatients with uncomplicated illness who are not at increased risk for complications  (
         <a class="graphic graphic_table graphicRef72029" href="/z/d/graphic/72029.html" rel="external">
          table 1
         </a>
         ), treatment should be guided by duration of symptoms  (
         <a class="graphic graphic_algorithm graphicRef140873" href="/z/d/graphic/140873.html" rel="external">
          algorithm 1
         </a>
         ) (see
         <a class="local">
          'Patients who are not at high risk for complications or transmission'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Symptoms &lt;48 hours
         </strong>
         − For patients within 48 hours of symptom onset, whether to administer antiviral treatment should be guided by individual patient circumstances; treatment may be associated with a modest reduction in duration of illness (by approximately 24 hours).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Symptoms ≥48 hours
         </strong>
         − For patients beyond 48 hours of symptom onset, we suggest not administering antiviral treatment (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), given lack of benefit.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antiviral selection
         </strong>
         − For outpatients with influenza, we suggest treatment with
         <a class="drug drug_general" data-topicid="9460" href="/z/d/drug information/9460.html" rel="external">
          oseltamivir
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ); it is the agent with the most established efficacy and safety data. Alternative agents include inhaled
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         and oral
         <a class="drug drug_general" data-topicid="119458" href="/z/d/drug information/119458.html" rel="external">
          baloxavir
         </a>
         . Dosing is summarized in the table  (
         <a class="graphic graphic_table graphicRef50350" href="/z/d/graphic/50350.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Antiviral selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Infection control and returning to work/school
         </strong>
         − Use of face masks and hand hygiene may reduce household transmission. Individuals with influenza should remain home from work, school, and other public places until at least 24 hours after resolution of fever (without use of antipyretics) and improvement in symptoms. (See
         <a class="local">
          'Infection control and returning to work/school'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antiviral resistance
         </strong>
         − Antiviral resistance is rare; risk factors include administration of postexposure prophylaxis, prolonged antiviral treatment, and immunosuppression. For patients with suspected or known infection due to oseltamivir-resistant influenza virus, we suggest treatment with
         <a class="drug drug_general" data-topicid="10323" href="/z/d/drug information/10323.html" rel="external">
          zanamivir
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Antiviral resistance'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Centers for Disease Control and Prevention. Influenza antiviral medications: Summary for clinicians. https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm (Accessed on October 22, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa. Clin Infect Dis 2019; 68:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uyeki TM. Influenza. Ann Intern Med 2021; 174:ITC161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; 2:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lytras T, Mouratidou E, Andreopoulou A, et al. Effect of Early Oseltamivir Treatment on Mortality in Critically Ill Patients With Different Types of Influenza: A Multiseason Cohort Study. Clin Infect Dis 2019; 69:1896.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu J, Santesso N, Mustafa R, et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med 2012; 156:512.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katzen J, Kohn R, Houk JL, Ison MG. Early Oseltamivir After Hospital Admission Is Associated With Shortened Hospitalization: A 5-Year Analysis of Oseltamivir Timing and Clinical Outcomes. Clin Infect Dis 2019; 69:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venkatesan S, Myles PR, Bolton KJ, et al. Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection. J Infect Dis 2020; 221:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Welch SC, Lam SW, Neuner EA, et al. High-dose versus standard dose oseltamivir for treatment of severe influenza in adult intensive care unit patients. Intensive Care Med 2015; 41:1365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pai MP, Lodise TP Jr. Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary. Antimicrob Agents Chemother 2011; 55:5640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duval X, van der Werf S, Blanchon T, et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med 2010; 7:e1000362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar D, Ison MG, Mira JP, et al. Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial. Lancet Infect Dis 2022; 22:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beigel JH, Bao Y, Beeler J, et al. Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial. Lancet Infect Dis 2017; 17:1255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Jong MD, Ison MG, Monto AS, et al. Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. Clin Infect Dis 2014; 59:e172.
          </a>
         </li>
         <li class="breakAll">
          Dectova. GlaxoSmithKline, Italy. https://www.ema.europa.eu/en/documents/product-information/dectova-epar-product-information_en.pdf (Accessed on February 16, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           To KK, Hung IF, Li IW, et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis 2010; 50:850.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreno G, Carbonell R, Díaz E, et al. Effectiveness of prolonged versus standard-course of oseltamivir in critically ill patients with severe influenza infection: A multicentre cohort study. J Med Virol 2023; 95:e29010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chertow DS, Memoli MJ. Bacterial coinfection in influenza: a grand rounds review. JAMA 2013; 309:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hanula R, Bortolussi-Courval É, Mendel A, et al. Evaluation of Oseltamivir Used to Prevent Hospitalization in Outpatients With Influenza: A Systematic Review and Meta-Analysis. JAMA Intern Med 2024; 184:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015; 385:1729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2014; :CD008965.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med 2018; 379:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ison MG, Portsmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis 2020; 20:1204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butler CC, van der Velden AW, Bongard E, et al. Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. Lancet 2020; 395:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fry AM, Goswami D, Nahar K, et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis 2014; 14:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boivin G. Detection and management of antiviral resistance for influenza viruses. Influenza Other Respir Viruses 2013; 7 Suppl 3:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hurt AC, Chotpitayasunondh T, Cox NJ, et al. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis 2012; 12:240.
          </a>
         </li>
         <li class="breakAll">
          Centers for Disease Control and Prevention. Past Flu Seasons. https://www.cdc.gov/flu/season/past-flu-seasons.htm (Accessed on October 14, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawai N, Ikematsu H, Hirotsu N, et al. Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons. Clin Infect Dis 2009; 49:1828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jefferson T, Jones M, Doshi P, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014; 348:g2545.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burch J, Corbett M, Stock C, et al. Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aoki FY, Boivin G. Influenza virus shedding: excretion patterns and effects of antiviral treatment. J Clin Virol 2009; 44:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283:1016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venkatesan S, Myles PR, Leonardi-Bee J, et al. Impact of Outpatient Neuraminidase Inhibitor Treatment in Patients Infected With Influenza A(H1N1)pdm09 at High Risk of Hospitalization: An Individual Participant Data Metaanalysis. Clin Infect Dis 2017; 64:1328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee N, Chan PK, Choi KW, et al. Factors associated with early hospital discharge of adult influenza patients. Antivir Ther 2007; 12:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaves SS, Pérez A, Miller L, et al. Impact of Prompt Influenza Antiviral Treatment on Extended Care Needs After Influenza Hospitalization Among Community-Dwelling Older Adults. Clin Infect Dis 2015; 61:1807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawai N, Ikematsu H, Iwaki N, et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons. Clin Infect Dis 2006; 43:439.
          </a>
         </li>
         <li class="breakAll">
          Tamiflu (oseltamivir phophate) capsules, for oral use, and oral suspension, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021087s069,021246s052lbl.pdf (Accessed on November 02, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Casscells SW, Granger E, Kress AM, Linton A. The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21 years diagnosed with influenza. Int J Adolesc Med Health 2009; 21:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huh K, Kang M, Shin DH, et al. Oseltamivir and the Risk of Neuropsychiatric Events: A National, Population-based Study. Clin Infect Dis 2020; 71:e409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heneghan CJ, Onakpoya I, Thompson M, et al. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014; 348:g2547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marty FM, Vidal-Puigserver J, Clark C, et al. Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. Lancet Respir Med 2017; 5:135.
          </a>
         </li>
         <li class="breakAll">
          Relenza (zanamivir inhalation powder), for oral inhalation use, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021036s030lbl.pdf (Accessed on January 14, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiatboonsri S, Kiatboonsri C, Theerawit P. Fatal respiratory events caused by zanamivir nebulization. Clin Infect Dis 2010; 50:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kohno S, Yen MY, Cheong HJ, et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother 2011; 55:5267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen HD, Wang X, Yu SL, et al. Clinical Effectiveness of Intravenous Peramivir Compared With Oseltamivir in Patients With Severe Influenza A With Primary Viral Pneumonia: A Randomized Controlled Study. Open Forum Infect Dis 2021; 8:ofaa562.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wakabayashi T, Nakatsuji T, Kambara H, et al. Drug-induced Neuropsychiatric Adverse Events Using Post-Marketing Surveillance. Curr Rev Clin Exp Pharmacol 2022; 17:144.
          </a>
         </li>
         <li class="breakAll">
          Xofluza (baloxavir marboxil) for oral use, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210854s001lbl.pdf (Accessed on October 17, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marty FM, Man CY, van der Horst C, et al. Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study. J Infect Dis 2014; 209:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan-Tack KM, Murray JS, Birnkrant DB. Use of ribavirin to treat influenza. N Engl J Med 2009; 361:1713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin Infect Dis 2009; 48 Suppl 1:S3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lansbury L, Rodrigo C, Leonardi-Bee J, et al. Corticosteroids as adjunctive therapy in the treatment of influenza. Cochrane Database Syst Rev 2019; 2:CD010406.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pastores SM, Annane D, Rochwerg B, Corticosteroid Guideline Task Force of SCCM and ESICM. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part II): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Med 2018; 44:474.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davey RT Jr, Fernández-Cruz E, Markowitz N, et al. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial. Lancet Respir Med 2019; 7:951.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6998 Version 106.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Centers for Disease Control and Prevention. Influenza antiviral medications: Summary for clinicians. https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm (Accessed on October 22, 2020).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30566567" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenzaa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34748378" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Influenza.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24815805" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30753349" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Effect of Early Oseltamivir Treatment on Mortality in Critically Ill Patients With Different Types of Influenza: A Multiseason Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22371849" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30304487" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Early Oseltamivir After Hospital Admission Is Associated With Shortened Hospitalization: A 5-Year Analysis of Oseltamivir Timing and Clinical Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31314899" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25952823" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : High-dose versus standard dose oseltamivir for treatment of severe influenza in adult intensive care unit patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21930881" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Oseltamivir and oseltamivir carboxylate pharmacokinetics in obese adults: dose modification for weight is not necessary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21072246" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35085510" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28958678" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza: a multicentre, double-blind, randomised phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25115871" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25115871" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20136415" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37537755" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Effectiveness of prolonged versus standard-course of oseltamivir in critically ill patients with severe influenza infection: A multicentre cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23321766" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Bacterial coinfection in influenza: a grand rounds review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37306992" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Evaluation of Oseltamivir Used to Prevent Hospitalization in Outpatients With Influenza: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25640810" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24718923" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30184455" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32526195" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31839279" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24268590" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24215378" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Detection and management of antiviral resistance for influenza viruses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22186145" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22186145" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19911968" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Clinical effectiveness of oseltamivir and zanamivir for treatment of influenza A virus subtype H1N1 with the H274Y mutation: a Japanese, multicenter study of the 2007-2008 and 2008-2009 influenza seasons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24811411" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19665930" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19272835" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Influenza virus shedding: excretion patterns and effects of antiviral treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10697061" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28199524" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Impact of Outpatient Neuraminidase Inhibitor Treatment in Patients Infected With Influenza A(H1N1)pdm09 at High Risk of Hospitalization: An Individual Participant Data Metaanalysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17668558" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Factors associated with early hospital discharge of adult influenza patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26334053" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Impact of Prompt Influenza Antiviral Treatment on Extended Care Needs After Influenza Hospitalization Among Community-Dwelling Older Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16838232" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16838232" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: a Japanese multicenter study of the 2003-2004 and 2004-2005 influenza seasons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19526698" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The association between oseltamivir use and adverse neuropsychiatric outcomes among TRICARE beneficiaries, ages 1 through 21 years diagnosed with influenza.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31996920" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Oseltamivir and the Risk of Neuropsychiatric Events: A National, Population-based Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24811412" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28094141" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28094141" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20095840" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Fatal respiratory events caused by zanamivir nebulization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21825298" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33447633" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Clinical Effectiveness of Intravenous Peramivir Compared With Oseltamivir in Patients With Severe Influenza A With Primary Viral Pneumonia: A Randomized Controlled Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33588740" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Drug-induced Neuropsychiatric Adverse Events Using Post-Marketing Surveillance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33588740" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Drug-induced Neuropsychiatric Adverse Events Using Post-Marketing Surveillance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23983212" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19846864" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Use of ribavirin to treat influenza.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19067613" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Developing new antiviral agents for influenza treatment: what does the future hold?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30798570" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Corticosteroids as adjunctive therapy in the treatment of influenza.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29090327" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part II): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31582358" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
